Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions.

Andersson, Roland LU ; Aho, Ursula LU orcid ; Nilsson, Bo ; Peters, Godefridus ; Pastor-Anglada, Marcal ; Rasch, Wenche and Sandvold, Marit (2009) In Scandinavian Journal of Gastroenterology 44. p.782-786
Abstract
Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1... (More)
Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1 expression. Modifications of gemcitabine not rendering it dependent on the nucleoside transporter may be a successful future mode of chemotherapy treatment, and determination of the nucleoside receptor status at the time of diagnosis could potentially also contribute to a more targeted therapy in the future. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Gastroenterology
volume
44
pages
782 - 786
publisher
Taylor & Francis
external identifiers
  • wos:000268579400003
  • pmid:19214867
  • scopus:70350635407
  • pmid:19214867
ISSN
1502-7708
DOI
10.1080/00365520902745039
language
English
LU publication?
yes
id
0340dab7-0cd1-48b5-b48d-4b1196e0f759 (old id 1302576)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19214867?dopt=Abstract
date added to LUP
2016-04-04 09:40:36
date last changed
2022-01-29 18:59:40
@article{0340dab7-0cd1-48b5-b48d-4b1196e0f759,
  abstract     = {{Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1 expression. Modifications of gemcitabine not rendering it dependent on the nucleoside transporter may be a successful future mode of chemotherapy treatment, and determination of the nucleoside receptor status at the time of diagnosis could potentially also contribute to a more targeted therapy in the future.}},
  author       = {{Andersson, Roland and Aho, Ursula and Nilsson, Bo and Peters, Godefridus and Pastor-Anglada, Marcal and Rasch, Wenche and Sandvold, Marit}},
  issn         = {{1502-7708}},
  language     = {{eng}},
  pages        = {{782--786}},
  publisher    = {{Taylor & Francis}},
  series       = {{Scandinavian Journal of Gastroenterology}},
  title        = {{Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions.}},
  url          = {{http://dx.doi.org/10.1080/00365520902745039}},
  doi          = {{10.1080/00365520902745039}},
  volume       = {{44}},
  year         = {{2009}},
}